NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

LC,



Avoid disinformation and bad-faith rumors posted on social media. That’s what we teach our children and that is what we all need to do.

Examples of reasonably valid credentialed sources to consider (because their analyses and decisions have real impact):

✅️ Judges
✅️ Government Regulators
✅️ Independent Peer Review
✅️ U.S. National Institutes of Health
✅️ UCLA
✅️ King’s College

Seek full-context sources, and consider the full body of evidence and findings from all clinical, regulatory, or legal processes.

Try to keep your focus from drifting too far from 🌍 … Here on Earth, we are looking forward as the novel DCVax-L cell-based platform technology enters the regulatory phase of its journey. The United States and United Kingdom are largely responsible for developing DCVax-L, and the U.S. and U.K. will lead the novel technology through a global regulatory process.

Combo is King!




https://www.nature.com/articles/s41420-023-01782-7

https://www.jci.org/articles/view/169314






https://www.fda.gov/drugs/our-perspective/50-years-progress-treating-patients-cancer

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

https://www.raps.org/News-and-Articles/News-Articles/2023/9/FDA%E2%80%99s-Califf-Expect-to-see-more-RWE-based-regulato

https://www.raps.org/news-and-articles/news-articles/2023/8/fda-finalizes-guidance-on-real-world-evidence-in-d


https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html

March 2023

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html

February 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html

August 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html

July 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html

December 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html


https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

In my view, the short list of pre-commercial milestones that stand out and shine the most:

⭐️ JAMA Oncology
⭐️ Multiple MHRA Approvals
⭐️ Emerging Combo Data
⭐️ MAA Submission

Further, Dr. Liau joining the SAB at Northwest Biotherapeutics is awesome!

Combo is King!

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

I would count Doctors Liau and Ashkan among the soldiers—fighting disease with their novel cell-based technology! Liau and Ashkan both are extremely noteworthy as we look back on the P3 and as we look forward to the regulatory phase in the UK, US, and other nations…

UCLA, King’s College, JAMA Oncology, and Brown University are some excellent sources that you might wish to consider in reference to the reputation of Northwest Biotherapeutics and those who choose to associate with the company, its SAB, and with the novel DCVax® technology.

The world-renowned doctors cited below worked on the P3 and were coauthors of a DCVax-L publication along with Dr. Bosch of Northwest Biotherapeutics.

Furthermore, both Liau and Ashkan have had the support their respective nations’ governments over many years. Ashkan is an advisor to the UK government, and Liau’s work has been supported by NIH peer-reviewed grants for 20 consecutive years.

https://www.kch.nhs.uk/news/kings-team-wins-professional-excellence-award/


https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html


https://labusinessjournal.com/healthcare/national-academy-medicine-taps-ucla-neurosurgeon/


https://pubmed.ncbi.nlm.nih.gov/33789235/

https://www.societyns.org/about/officers-detail/linda-m-liau-md-phd-mba-4

This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt

— JAMA Oncology (@JAMAOnc) February 15, 2023

#dcvax #allsolidtumors $nwbo #gbm

Great to see, congratulations Linda Liau winning the Charles B. Wilson Excellence Award 2023:

Established by the Brain Tumor Society in 2004, this award recognizes outstanding contributions of a clinician to the field of neuro-oncology.… pic.twitter.com/6L7rhyoNU4

— Peter Davis (@peter_brit) October 3, 2023

https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/